Nov. 5, 2014, 12:49 PM
Apr. 9, 2014, 12:45 PM
Mar. 26, 2014, 5:35 PM
- Essex Property Trust (ESS) +2.2% AH on news it will replace Cliffs Natural Resources (CLF) in the S&P 500 after the close of trading April 1.
- CLF will move down to the S&P MidCap 400, replacing ESS.
- FEI Co. (FEIC) will replace BRE Properties (BRE), which is being acquired by Essex, in the MidCap 400, and Fabrinet (FN) will replace FEI in the S&P SmallCap 600.
- Also, Albany Molecular Research (AMRI) will replace Supertex (SUPX), which is being acquired, in the SmallCap 600.
- AMRI +4.2%, FEIC +2%, FN +1.5%, CLF -1.3% AH.
Dec. 3, 2013, 10:18 AM
- Albany Molecular Research (AMRI -10%) slides hard in morning trading.
- Sterne Agee has cut the shares to Neutral from Buy.
- Price target is now $12 (from $15).
- Here's analyst Greg Bolan: "As we have written multiple times, we believe CRO valuations are expensive and therefore have a difficult time seeing AMRI generate a strong return through acquisition(s)."
Aug. 12, 2013, 2:00 PM
- Albany Molecular Research (AMRI -13.2%) plunges after an SEC filing shows Bristol-Myers (BMY -1.4%) has terminated the development of the triple reuptake inhibitor BMS-820836.
- According to BMY, the investigational drug failed to show superiority over duloxetine or escitalopram in a Phase II study for Treatment Resistant Depression.
- AMRI says the news will have "no impact on [its] financial guidance or forecasts." (8-K)
Jun. 12, 2013, 2:44 PM
The profitability of Albany Molecular's (AMRI +9.9%) "core business could reach historic levels," Sterne Agee says, citing the expected "resurgence in preclinical-PI activity over the next several years." Analyst Greg Bolan resumes coverage at Buy with a $15 price target.| Jun. 12, 2013, 2:44 PM
May 7, 2013, 12:52 PM
Feb. 13, 2013, 12:45 PM
Feb. 12, 2013, 12:45 PM
Feb. 12, 2013, 12:20 PM
Albany Molecular Research (AMRI +18%) surges after its FQ3 easily blows out estimates this morning. Contract revenue was $59.1M, up 50% from the prior-year period with sequential revenue improvement in Discovery and Large Scale Manufacturing services. Contract margin jumped to 18% from 2% in the prior-year period. The company also forecast an upbeat Q4, now expecting an EPS of $0.08 - $0.12, better than the Street view of $0.06.| Feb. 12, 2013, 12:20 PM
Jan. 22, 2013, 12:45 PM
Nov. 6, 2012, 10:30 AMAlbany Molecular Research (AMRI +11%) pops after beating on its Q3 bottom line this morning. Total sales were up 11.2% Y/Y on stronger royalty and contract revenues, particularly in its large-scale manufacturing segment. The company also boosts its outlook for FY12 as well as Q4. It now sees FY12 earnings coming in between $0.10 and $0.16 per share, towards the top-end of the Street's $0.12 consensus, and for Q4, its EPS is targeted to be $0.08 to $0.12, also better than the Street view of $0.06. | Nov. 6, 2012, 10:30 AM
Feb. 7, 2012, 8:15 AMAlbany Molecular Research (AMRI): Q4 EPS of -$0.19 misses by $0.05. Revenue of $46.6M (-4.1% Y/Y) misses by $2M. Shares -8.8% premarket. (PR) | Feb. 7, 2012, 8:15 AM